Open Access
Issue
Published:
12 September 2023
Clinical utility of six serum tumor markers for the diagnosis of lung cancer
)
Download citation
229
Views
47
Downloads
2
Crossref
N/A
WoS
N/A
Scopus
N/A
CSCD
With the increasing prevalence of lung cancer, it has become imperative to identify reliable biomarkers that can aid in early detection and prognosis assessment. Therefore, we sought to investigate the potential utility of six serum tumor markers as diagnostic and prognostic tools for lung cancer patients. By analyzing a large cohort of patients with different stages and subtypes of lung cancer, we hoped to shed light on the predictive value and accuracy of each marker individually, as well as their combined performance. This study should not only provide valuable insights into the biology and pathogenesis of lung cancer but also pave the way for personalized treatment strategies based on individual patient profiles.
The serum levels of the tumor markers progastrin‐releasing peptide (ProGRP), carcinoembryonic antigen (CEA), neuron‐specific enolase (NSE), cytokeratin 19 fragment (CYFRA21‐1), carbohydrate antigen 19‐9 (CA19‐9) and squamous cell carcinoma antigen (SCCA) were meticulously assessed in a cohort comprising 324 individuals diagnosed with lung cancer and an additional 51 patients with benign lung disease. The measurements were conducted using cutting‐edge techniques such as ELISA, electrochemical luminescence, and chemiluminescence methods. Differences between groups and the impact of these markers on lung cancer diagnosis were analyzed.
The serum levels of ProGRP, NSE, and CEA were significantly higher in lung cancer patients than in patients with benign lung disease (p < 0.01). NSE had the highest sensitivity for squamous cell carcinomas (SC), while CEA had the highest sensitivity for adenocarcinomas (AC). ProGRP and NSE had higher sensitivities than other markers for small cell carcinomas (SCC). Combining the six tumor markers resulted in higher sensitivities for SC (70.6%), AC (77.4%), and SCC (80%) compared with any single test. Receiver operator characteristic analysis showed that ProGRP and NSE had a greater area under the curve (AUC) in SCC (0.886 and 0.775) than SC and AC, while CEA had a higher AUC in AC (0.716), and NSE had a higher AUC than other markers in SC (0.719).
ProGRP and NSE are effective serum tumor markers for SCC, whereas CEA and NSE may aid in the diagnosis of AC and SC. Combining the detection of ProGRP, NSE, CYFRA21‐1, CEA, and SCCA significantly improves sensitivity when diagnosing lung cancer.
menu
Clinical utility of six serum tumor markers for the diagnosis of lung cancer
)
Abstract
With the increasing prevalence of lung cancer, it has become imperative to identify reliable biomarkers that can aid in early detection and prognosis assessment. Therefore, we sought to investigate the potential utility of six serum tumor markers as diagnostic and prognostic tools for lung cancer patients. By analyzing a large cohort of patients with different stages and subtypes of lung cancer, we hoped to shed light on the predictive value and accuracy of each marker individually, as well as their combined performance. This study should not only provide valuable insights into the biology and pathogenesis of lung cancer but also pave the way for personalized treatment strategies based on individual patient profiles.
The serum levels of the tumor markers progastrin‐releasing peptide (ProGRP), carcinoembryonic antigen (CEA), neuron‐specific enolase (NSE), cytokeratin 19 fragment (CYFRA21‐1), carbohydrate antigen 19‐9 (CA19‐9) and squamous cell carcinoma antigen (SCCA) were meticulously assessed in a cohort comprising 324 individuals diagnosed with lung cancer and an additional 51 patients with benign lung disease. The measurements were conducted using cutting‐edge techniques such as ELISA, electrochemical luminescence, and chemiluminescence methods. Differences between groups and the impact of these markers on lung cancer diagnosis were analyzed.
The serum levels of ProGRP, NSE, and CEA were significantly higher in lung cancer patients than in patients with benign lung disease (p < 0.01). NSE had the highest sensitivity for squamous cell carcinomas (SC), while CEA had the highest sensitivity for adenocarcinomas (AC). ProGRP and NSE had higher sensitivities than other markers for small cell carcinomas (SCC). Combining the six tumor markers resulted in higher sensitivities for SC (70.6%), AC (77.4%), and SCC (80%) compared with any single test. Receiver operator characteristic analysis showed that ProGRP and NSE had a greater area under the curve (AUC) in SCC (0.886 and 0.775) than SC and AC, while CEA had a higher AUC in AC (0.716), and NSE had a higher AUC than other markers in SC (0.719).
ProGRP and NSE are effective serum tumor markers for SCC, whereas CEA and NSE may aid in the diagnosis of AC and SC. Combining the detection of ProGRP, NSE, CYFRA21‐1, CEA, and SCCA significantly improves sensitivity when diagnosing lung cancer.
References(14)
Seelan LJ, Suresh LP, K S A, P K V. Computer‐aided detection of human lung nodules on computer tomography images via novel optimized techniques. Curr Med Imaging. 2022;18(12):1282–90. https://doi.org/10.2174/1573405617666211126151713
Xu K, Zhang C, Du T, Gabriel ANA, Wang X, Li X, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021;134:111111. https://doi.org/10.1016/j.biopha.2020.111111
Li J, Chen Y, Wang X, Wang C, Xiao M. The value of combined detection of CEA, CYFRA21‐1, SCC‐Ag, and pro‐GRP in the differential diagnosis of lung cancer. Transl Cancer Res. 2021;10(4):1900–6. https://doi.org/10.21037/tcr‐21‐527
Du J, Li Y, Wang L, Zhou Y, Shen Y, Xu F, et al. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer. Clin Chim Acta. 2020;509:295–303. https://doi.org/10.1016/j.cca.2020.06.037
Wu LH, Chen L, Wang QY, Wang YT. Correlation between HRCT signs and levels of CA125, SCCA, and NSE for different pathological types of lung cancer. Eur Rev Med Pharmacol Sci. 2023;27(9):4162–8. https://doi.org/10.26355/eurrev_202305_32325
Svaton M, Blazek J, Krakorova G, Pesek M, Buresova M, Teufelova Z, et al. Prognostic role for CYFRA 21‐1 in patients with advanced‐stage NSCLC treated with bevacizumab plus chemotherapy. Anticancer Res. 2021;41(4):2053–8. https://doi.org/10.21873/anticanres.14974
Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, et al. Serum CA 19‐9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54(3):643–9. https://doi.org/10.3349/ymj.2013.54.3.643
Pothal S, Patil KP, Manjhi R, Dutta P. Diagnostic efficacy of broncho‐alveolar lavage carcino‐embronic antigen in carcinoma of lung. J Fam Med Prim Care. 2019;8(5):1725–9. https://doi.org/10.4103/jfmpc.jfmpc_119_19
Zhu H. Squamous cell carcinoma antigen: clinical application and research status. Diagnostics. 2022;12(5):1065. https://doi.org/10.3390/diagnostics12051065
Xu G, Shi W, Ling L, Li C, Shao F, Chen J, et al. Differential expression and analysis of extrachromosomal circular DNAs as serum biomarkers in lung adenocarcinoma. J Clin Lab Anal. 2022;36(6):e24425. https://doi.org/10.1002/jcla.24425
Zhou W, Yang F, Peng J, Wang F, Lin Y, Jiang W, et al. High pretreatment serum CA19‐9 level predicts a poor prognosis for patients with stage Ⅲ colon cancer after curative resection and adjuvant chemotherapy. J Cancer. 2019;10(16):3810–8. https://doi.org/10.7150/jca.31375
Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun. 2021;41(12):1257–74. https://doi.org/10.1002/cac2.12204
Atherly AJ, Camidge DR. The cost‐effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106(6):1100–6. https://doi.org/10.1038/bjc.2012.60
Hou JX, Yang XQ, Chen C, Jiang Q, Yang GL, Li Y. Screening the gastric cancer related tumor markers from multi‐tumor markers protein chip with kappa coefficient and cost‐effectiveness analysis. Hepatogastroenterology. 2011;58(106):632–6.
Publication history
Copyright
Acknowledgements
We would like to thank all those who participated in the study for their time and involvement.
Rights and permissions
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
FEEDBACK 
TOP